Rchr
J-GLOBAL ID:201801007147906954   Update date: Jan. 30, 2024

Ko Sato

Ko Sato
Research field  (1): Tumor biology
Research theme for competitive and other funds  (2):
  • 2015 - 2018 The effect of oestrogen with BRCA1 dysfunction on carcinogenesis
  • 2011 - 2013 Drug sensitivity of PLK1-overexpressing cancer
Papers (19):
  • Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana G Z Lim, Brendan N K Pang, Sherlly Lim, Joe P S Yeong, et al. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO molecular medicine. 2021. e13366
  • Teppei Iwata, Anna S Sedukhina, Manabu Kubota, Shigeko Oonuma, Ichiro Maeda, Miki Yoshiike, Wataru Usuba, Kimino Minagawa, Eleina Hames, Rei Meguro, et al. A new bioinformatics approach identifies overexpression of GRB2 as a poor prognostic biomarker for prostate cancer. Scientific reports. 2021. 11. 1. 5696-5696
  • Keiko Oda-Kawashima, Anna S Sedukhina, Naoki Okamoto, Mariya Lytvyn, Kimino Minagawa, Teppei Iwata, Toshio Kumai, Eri Sato, Eiichi Inada, Ayako Yamaura, et al. NF-kB signaling in cardiomyocytes is inhibited by sevoflurane and promoted by propofol. FEBS open bio. 2020
  • Anna Sedukhina, Ko Sato. Multistep in silico analysis for precision oncology in triple negative breast cancer. CANCER SCIENCE. 2018. 109. 452-452
  • Ko Sato. Two kills with one shot: A biomarker with therapeutic implications in poor prognosis gastric cancers. CANCER RESEARCH. 2017. 77. 22
more...
MISC (35):
Patents (1):
Professional career (1):
  • 医学博士 (聖マリアンナ医科大学)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page